{"id":"6242bf65e3b3","type":"article","url":"https://hartvaat.nl/2017/02/14/doac-s-bij-af-met-kleplijden-excl-significante-mitralisstenose-meta-analyse/","title":"DOAC's bij AF met kleplijden (excl. significante mitralisstenose): meta-analyse","title_en":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.116.026793","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.116.026793","authors":["Konstantinos C Siontis","Xiaoxi Yao","Bernard J Gersh","Peter A Noseworthy"],"significance":8,"published":"2017-02-14","source_date":"2017-02-14","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis confirmed the safety and efficacy of DOACs in atrial fibrillation patients with valvular heart disease other than significant mitral stenosis or mechanical heart valves, supporting DOAC use in the broad spectrum of 'valvular' AF.","created":"2026-07-03T10:26:33Z","updated":"2026-07-03T13:25:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse die de veiligheid en werkzaamheid van DOAC's bevestigt bij AF-patiënten met klepafwijkingen anders dan significante mitralisstenose of mechanische klepprothese. Verruimt de DOAC-indicatie.","abstract_original":""}